Protective DNA vaccination against myelin oligodendrocyte glycoprotein is overcome by C3d in experimental autoimmune encephalomyelitis

Molecular Immunology

Volumn 44, Issue 15, 2007, Pages 3691-3701

  Jégou, Jean François ^a   Chan, Philippe ^a   Schouft, Marie Thérèse ^a   Gasque, Philippe ^b   Vaudry, Hubert ^a   Fontaine, Marc ^a  

^a INSERM   (France)

^b LBGM   (France)

Author keywords

Autoimmunity; Complement; DNA vaccination; Experimental autoimmune encephalomyelitis; Myelin oligodendrocyte glycoprotein

Indexed keywords

COMPLEMENT COMPONENT C3D; COMPLEMENT RECEPTOR; COMPLEMENT RECEPTOR 2; DNA VACCINE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNITY; CELL STRAIN COS7; CONTROLLED STUDY; DISEASE MODEL; DNA IMMUNIZATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; CERCOPITHECUS AETHIOPS; COMPLEMENT C3D; COS CELLS; DENDRITIC CELLS; DNA; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; MACROPHAGES; MICE; MICE, INBRED C57BL; MYELIN-ASSOCIATED GLYCOPROTEIN; T-LYMPHOCYTES; VACCINATION; VACCINES, DNA;

MUS;

EID: 34249747316     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2007.04.008     Document Type: Article

References (63)

1. Ahearn J.M., Fischer M.B., Croix D., Goerg S., Ma M., Xia J., Zhou X., Howard R.G., Rothstein T.L., and Carroll M.C. Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen. Immunity 4 (1996) 251-262
2. Baker D., and Hankey D.J. Gene therapy in autoimmune, demyelinating disease of the central nervous system. Gene Ther. 10 (2003) 844-853
3. Balasa B., Boehm B.O., Fortnagel A., Karges W., Van Gunst K., Jung N., Camacho S.A., Webb S.R., and Sarvetnick N. Vaccination with glutamic acid decarboxylase plasmid DNA protects mice from spontaneous autoimmune diabetes and B7/CD28 costimulation circumvents that protection. Clin. Immunol. 99 (2001) 241-252
4. Barrington R.A., Zhang M., Zhong X., Jonsson H., Holodick N., Cherukuri A., Pierce S.K., Rothstein T.L., and Carroll M.C. CD21/CD19 coreceptor signaling promotes B cell survival during primary immune responses. J. Immunol. 175 (2005) 2859-2867
5. Bergmann-Leitner E.S., Scheiblhofer S., Weiss R., Duncan E.H., Leitner W.W., Chen D., Angov E., Khan F., Williams J.L., Winter D.B., Thalhamer J., Lyon J.A., and Tsokos G.C. C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria. Int. Immunol. 17 (2005) 245-255
6. Boackle S.A. Complement and autoimmunity. Biomed. Pharmacother. 57 (2003) 269-273
7. Boackle S.A., Holers V.M., Chen X., Szakonyi G., Karp D.R., Wakeland E.K., and Morel L. Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein. Immunity 15 (2001) 775-785
8. Boackle S.A., Morris M.A., Holers V.M., and Karp D.R. Complement opsonization is required for presentation of immune complexes by resting peripheral blood B cells. J. Immunol. 161 (1998) 6537-6543
9. Botto M., Dell'Agnola C., Bygrave A.E., Thompson E.M., Cook H.T., Petry F., Loos M., Pandolfi P.P., and Walport M.J. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet. 19 (1998) 56-59
10. Bourquin C., Iglesias A., Berger T., Wekerle H., and Linington C. Myelin oligodendrocyte glycoprotein-DNA vaccination induces antibody-mediated autoaggression in experimental autoimmune encephalomyelitis. Eur. J. Immunol. 30 (2000) 3663-3671
11. Brink B.P., Veerhuis R., Breij E.C., van der Valk P., Dijkstra C.D., and Bo L. The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions. J. Neuropathol. Exp. Neurol. 64 (2005) 147-155
12. Carroll M.C. A protective role for innate immunity in systemic lupus erythematosus. Nat. Rev. Immunol. 4 (2004) 825-831
13. Chen Z., Koralov S.B., and Kelsoe G. Complement C4 inhibits systemic autoimmunity through a mechanism independent of complement receptors CR1 and CR2. J. Exp. Med. 192 (2000) 1339-1352
14. Cherukuri A., Cheng P.C., and Pierce S.K. The role of the CD19/CD21 complex in B cell processing and presentation of complement-tagged antigens. J. Immunol. 167 (2001) 163-172
15. Costa O., Divoux D., Ischenko A., Tron F., and Fontaine M. Optimization of an animal model of experimental autoimmune encephalomyelitis achieved with a multiple MOG (35-55) peptide in C57BL6/J strain of mice. J. Autoimmun. 20 (2003) 51-61
16. Del Nagro C.J., Kolla R.V., and Rickert R.C. A critical role for complement C3d and the B cell coreceptor (CD19/CD21) complex in the initiation of inflammatory arthritis. J. Immunol. 175 (2005) 5379-5389
17. Dempsey P.W., Allison M.E., Akkaraju S., Goodnow C.C., and Fearon D.T. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271 (1996) 348-350
18. Domdey H., Wiebauer K., Kazmaier M., Muller V., Odink K., and Fey G. Characterization of the mRNA and cloned cDNA specifying the third component of mouse complement. Proc. Natl. Acad. Sci. U.S.A. 79 (1982) 7619-7623
19. Donnelly J.J., Ulmer J.B., Shiver J.W., and Liu M.A. DNA vaccines. Annu. Rev. Immunol. 15 (1997) 617-648
20. Fearon D.T., and Carroll M.C. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu. Rev. Immunol. 18 (2000) 393-422
21. Fischer M.B., Goerg S., Shen L., Prodeus A.P., Goodnow C.C., Kelsoe G., and Carroll M.C. Dependence of germinal center B cells on expression of CD21/CD35 for survival. Science 280 (1998) 582-585
22. Garren H., Ruiz P.J., Watkins T.A., Fontoura P., Nguyen L.T., Estline E.R., Hirschberg D.L., and Steinman L. Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. Immunity 15 (2001) 15-22
23. Gay D., and Esiri M. Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytological study. Brain 114 Pt 1B (1991) 557-572
24. Goodnow C.C., Sprent J., Fazekas de St Groth B., and Vinuesa C.G. Cellular and genetic mechanisms of selftolerance and autoimmunity. Nature 435 (2005) 590-597
25. Gor D.O., Ding X., Li Q., and Greenspan N.S. Genetic fusion of three tandem copies of murine C3d sequences to diphtheria toxin fragment B elicits a decreased fragment B-specific antibody response. Immunol. Lett. 102 (2006) 38-49
26. Green T.D., Montefiori D.C., and Ross T.M. Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. J. Virol. 77 (2003) 2046-2055
27. Green T.D., Newton B.R., Rota P.A., Xu Y., Robinson H.L., and Ross T.M. C3d enhancement of neutralizing antibodies to measles hemagglutinin. Vaccine 20 (2001) 242-248
28. Haas K.M., Toapanta F.R., Oliver J.A., Poe J.C., Weis J.H., Karp D.R., Bower J.F., Ross T.M., and Tedder T.F. Cutting edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression. J. Immunol. 172 (2004) 5833-5837
29. Hess M.W., Schwendinger M.G., Eskelinen E.L., Pfaller K., Pavelka M., Dierich M.P., and Prodinger W.M. Tracing uptake of C3dg-conjugated antigen into B cells via complement receptor type 2 (CR2, CD21). Blood 95 (2000) 2617-2623
30. Iglesias A., Bauer J., Litzenburger T., Schubart A., and Linington C. T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis. Glia 36 (2001) 220-234
31. Jégou J.F., Chan P., Schouft M.T., Gasque P., Vaudry H., and Fontaine M. C3d binding to the myelin oligodendrocyte glycoprotein results in an exacerbated experimental autoimmune encephalomyelitis. J. Immunol. 178 (2007) 3323-3331
32. Johns T.G., and Bernard C.C. The structure and function of myelin oligodendrocyte glycoprotein. J. Neurochem. 72 (1999) 1-9
33. Kaya Z., Afanasyeva M., Wang Y., Dohmen K.M., Schlichting J., Tretter T., Fairweather D., Holers V.M., and Rose N.R. Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nat. Immunol. 2 (2001) 739-745
34. Kozono Y., Abe R., Kozono H., Kelly R.G., Azuma T., and Holers V.M. Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells. J. Immunol. 160 (1998) 1565-1572
35. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G.A., and Klinman D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 (1995) 546-549
36. Lee Y., Haas K.M., Gor D.O., Ding X., Karp D.R., Greenspan N.S., Poe J.C., and Tedder T.F. Complement component C3d-antigen complexes can either augment or inhibit B lymphocyte activation and humoral immunity in mice depending on the degree of CD21/CD19 complex engagement. J. Immunol. 175 (2005) 8011-8023
37. Linares D., Echevarria I., and Mana P. Single-step purification and refolding of recombinant mouse and human myelin oligodendrocyte glycoprotein and induction of EAE in mice. Protein Expr. Purif. 34 (2004) 249-256
38. Linington C., Morgan B.P., Scolding N.J., Wilkins P., Piddlesden S., and Compston D.A. The role of complement in the pathogenesis of experimental allergic encephalomyelitis. Brain 112 Pt 4 (1989) 895-911
39. Lobell A., Weissert R., Eltayeb S., de Graaf K.L., Wefer J., Storch M.K., Lassmann H., Wigzell H., and Olsson T. Suppressive DNA vaccination in myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis involves a T1-biased immune response. J. Immunol. 170 (2003) 1806-1813
40. Lobell A., Weissert R., Eltayeb S., Svanholm C., Olsson T., and Wigzell H. Presence of CpG DNA and the local cytokine milieu determine the efficacy of suppressive DNA vaccination in experimental autoimmune encephalomyelitis. J. Immunol. 163 (1999) 4754-4762
41. Lobell A., Weissert R., Storch M.K., Svanholm C., de Graaf K.L., Lassmann H., Andersson R., Olsson T., and Wigzell H. Vaccination with DNA encoding an immunodominant myelin basic protein peptide targeted to Fc of immunoglobulin G suppresses experimental autoimmune encephalomyelitis. J. Exp. Med. 187 (1998) 1543-1548
42. Lyons J.A., San M., Happ M.P., and Cross A.H. B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur. J. Immunol. 29 (1999) 3432-3439
43. Mitchell J.A., Green T.D., Bright R.A., and Ross T.M. Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins. Vaccine 21 (2003) 902-914
44. Molina H., Holers V.M., Li B., Fung Y., Mariathasan S., Goellner J., Strauss-Schoenberger J., Karr R.W., and Chaplin D.D. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 3357-3361
45. Molina H., Kinoshita T., Inoue K., Carel J.C., and Holers V.M. A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2. J. Immunol. 145 (1990) 2974-2983
46. Morgan B.P., and Walport M.J. Complement deficiency and disease. Immunol. Today 12 (1991) 301-306
47. Pozdnyakova O., Guttormsen H.K., Lalani F.N., Carroll M.C., and Kasper D.L. Impaired antibody response to group B streptococcal type III capsular polysaccharide in C3- and complement receptor 2-deficient mice. J. Immunol. 170 (2003) 84-90
48. Prodeus A.P., Goerg S., Shen L.M., Pozdnyakova O.O., Chu L., Alicot E.M., Goodnow C.C., and Carroll M.C. A critical role for complement in maintenance of self-tolerance. Immunity 9 (1998) 721-731
49. Reynes M., Aubert J.P., Cohen J.H., Audouin J., Tricottet V., Diebold J., and Kazatchkine M.D. Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens. J. Immunol. 135 (1985) 2687-2694
50. Ross T.M., Xu Y., Bright R.A., and Robinson H.L. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat. Immunol. 1 (2000) 127-131
51. Ruiz P.J., Garren H., Ruiz I.U., Hirschberg D.L., Nguyen L.V., Karpuj M.V., Cooper M.T., Mitchell D.J., Fathman C.G., and Steinman L. Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: modulation of T cell costimulation. J. Immunol. 162 (1999) 3336-3341
52. Selmaj K., Kowal C., Walczak A., Nowicka J., and Raine C.S. Naked DNA vaccination differentially modulates autoimmune responses in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 111 (2000) 34-44
53. Shimizu I., Kawahara T., Haspot F., Bardwell P., Carroll M., and Sykes M. B-cell extrinsic CR1/CR2 promotes natural antibody production and tolerance induction of anti-{alpha}GAL-producing B-1 cells. Blood (2006)
54. Sospedra M., and Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23 (2005) 683-747
55. Suradhat S., Braun R.P., Lewis P.J., Babiuk L.A., van Drunen Littel-van den Hurk S., Griebel P.J., and Baca-Estrada M.E. Fusion of C3d molecule with bovine rotavirus VP7 or bovine herpesvirus type 1 glycoprotein D inhibits immune responses following DNA immunization. Vet. Immunol. Immunopathol. 83 (2001) 79-92
56. Test S.T., Mitsuyoshi J., Connolly C.C., and Lucas A.H. Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide. Infect. Immun. 69 (2001) 3031-3040
57. Tisch R., Wang B., Weaver D.J., Liu B., Bui T., Arthos J., and Serreze D.V. Antigen-specific mediated suppression of beta cell autoimmunity by plasmid DNA vaccination. J. Immunol. 166 (2001) 2122-2132
58. Tsunoda I., Kuang L.Q., Tolley N.D., Whitton J.L., and Fujinami R.S. Enhancement of experimental allergic encephalomyelitis (EAE) by DNA immunization with myelin proteolipid protein (PLP) plasmid DNA. J. Neuropathol. Exp. Neurol. 57 (1998) 758-767
59. Waisman A., Ruiz P.J., Hirschberg D.L., Gelman A., Oksenberg J.R., Brocke S., Mor F., Cohen I.R., and Steinman L. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nat. Med. 2 (1996) 899-905
60. Walport M.J., Davies K.A., Morley B.J., and Botto M. Complement deficiency and autoimmunity. Ann. N.Y. Acad. Sci. 815 (1997) 267-281
61. Weis J.J., Tedder T.F., and Fearon D.T. Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 81 (1984) 881-885
62. Weissert R., Lobell A., de Graaf K.L., Eltayeb S.Y., Andersson R., Olsson T., and Wigzell H. Protective DNA vaccination against organ-specific autoimmunity is highly specific and discriminates between single amino acid substitutions in the peptide autoantigen. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 1689-1694
63. Wu X., Jiang N., Deppong C., Singh J., Dolecki G., Mao D., Morel L., and Molina H.D. A role for the Cr2 gene in modifying autoantibody production in systemic lupus erythematosus. J. Immunol. 169 (2002) 1587-1592